Key Takeaways Skyrizi and Rinvoq momentum has restored AbbVie's top-line growth after Humira's U.S. patent loss.Strong demand in IBD and new indications like UC and GCA are expected to lift Q3 performance.ABBV is diversifying with rising sales in neuroscience and oncology, driven by newer therapies.AbbVie (ABBV) remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq. The robust demand for both drugs has helped the company retu ...